Non-ST-Segment Elevation Myocardial Infarction in Elderly Patients

The world population is aging, and cardiovascular diseases are the leading cause of death in Western countries. 

It is increasingly common to find patients aged 70 or older with non-ST-segment elevation acute myocardial infarction (NSTEMI). However, this group has been excluded from most studies, and there is not enough information to determine whether a conservative approach or invasive studies should be the preferred option.

Researchers conducted a meta-analysis including 1479 patients, half of whom underwent invasive treatment (INV) while the other half received conservative treatment (CON).

The primary endpoint (PEP) was all-cause mortality or myocardial infarction at one year of follow-up.

There were no significant differences in the studied population: the mean age was 84 years and 52% of patients were men; 79% had hypertension, 29% had diabetes, 15% had suffered a stroke, 35% had a previous myocardial infarction, 20% had undergone percutaneous coronary intervention (PCI), 13% had undergone myocardial revasculatization surgery, and 15% had atrial fibrillation.

Read also: QFR Analysis of Coronary Lesions with TAVR.

There were also no differences in the Killip classification at admission; most subjects were in Killip class 1.

The PEP at one year was similar between groups: 24.5% in the INV group and 28.9% in the CON group (95% confidence interval [CI]: 0.63–1.22; P = 0.43). There were no differences in mortality, but patients who received conservative treatment had a higher rate of myocardial infarction (19.1% vs. 12.2%, 95% CI 0.47–0.79; P = 0.0002) and a greater need for urgent revascularization (random-effects model hazard ratio [HR]: 0.41; 95% CI, 0.18–0.95; P = 0.037).

Conclusion

There was no evidence that routine invasive treatment in elderly patients with NSTEMI reduces the risk of all-cause mortality or myocardial infarction within one year compared with conservative treatment. However, there is compelling evidence that invasive treatment reduces the risk of recurrent myocardial infarction or need for urgent revascularization. More research through large-scale studies is needed.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Invasive vs. conservative management of older patients with non-ST-elevation acute coronary syndrome: individual patient data meta-analysis.

Reference: Christos P. Kotanidis, et al. European Heart Journal (2024) 45, 2052–2062 https://doi.org/10.1093/eurheartj/ehae151


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...